BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24512308)

  • 1. Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.
    Chueh AC; Tse JW; Tögel L; Mariadason JM
    Antioxid Redox Signal; 2015 Jul; 23(1):66-84. PubMed ID: 24512308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATF3 Repression of BCL-X
    Chüeh AC; Tse JWT; Dickinson M; Ioannidis P; Jenkins L; Togel L; Tan B; Luk I; Davalos-Salas M; Nightingale R; Thompson MR; Williams BRG; Lessene G; Lee EF; Fairlie WD; Dhillon AS; Mariadason JM
    Clin Cancer Res; 2017 Sep; 23(18):5573-5584. PubMed ID: 28611196
    [No Abstract]   [Full Text] [Related]  

  • 4. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction.
    Wilson AJ; Chueh AC; Tögel L; Corner GA; Ahmed N; Goel S; Byun DS; Nasser S; Houston MA; Jhawer M; Smartt HJ; Murray LB; Nicholas C; Heerdt BG; Arango D; Augenlicht LH; Mariadason JM
    Cancer Res; 2010 Jan; 70(2):609-20. PubMed ID: 20068171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.
    Bose P; Dai Y; Grant S
    Pharmacol Ther; 2014 Sep; 143(3):323-36. PubMed ID: 24769080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
    Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
    Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
    EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
    Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
    J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
    Brazelle W; Kreahling JM; Gemmer J; Ma Y; Cress WD; Haura E; Altiok S
    PLoS One; 2010 Dec; 5(12):e14335. PubMed ID: 21179472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors: multifunctional anticancer agents.
    Liu T; Kuljaca S; Tee A; Marshall GM
    Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
    Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
    Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells.
    De los Santos M; Zambrano A; Aranda A
    Mol Cancer Ther; 2007 Apr; 6(4):1425-32. PubMed ID: 17431121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells.
    Xu W; Liu H; Liu ZG; Wang HS; Zhang F; Wang H; Zhang J; Chen JJ; Huang HJ; Tan Y; Cao MT; Du J; Zhang QG; Jiang GM
    Cancer Lett; 2018 Apr; 420():1-13. PubMed ID: 29410023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1.
    Jang S; Jin H; Roy M; Ma AL; Gong S; Jaskula-Sztul R; Chen H
    Cancer Med; 2017 Sep; 6(9):2142-2152. PubMed ID: 28776955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death.
    Mrakovcic M; Kleinheinz J; Fröhlich LF
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.